卡格列净
医学
肾病
2型糖尿病
达帕格列嗪
糖尿病肾病
糖尿病
临床试验
2型糖尿病
内科学
内分泌学
药理学
重症监护医学
泌尿科
作者
Vlado Perkovic,Meg Jardine,Bruce Neal,Séverine Bompoint,Hiddo J.L. Heerspink,David M. Charytan,Robert Edwards,Rajiv Agarwal,George L. Bakris,Scott Bull,Christopher P. Cannon,George Capuano,Pei-Ling Chu,Dick de Zeeuw,Tom Greene,Adeera Levin,Carol A. Pollock,David C. Wheeler,Yshai Yavin,Hong Zhang
标识
DOI：10.1056/nejmoa1811744
摘要
Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI
Grayball
MchemG
迟大猫
开心岩
VDC
归尘
迷人秋烟
iNk
小白
andrele
竹筏过海
笔记本
遇上就这样吧
英勇的鼠标
小杨同学
YSM
zho
back you up
Xiaoxiao
从容芮
皖公网安备34019202002308
